Kallyope

Kallyope

Kallyope

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gutbrain axis.
Type
B2b
Founded
2015
Raised
$199M
Follow us
Alexa global traffic share
Latest funding Show all
$112,000,000
Venture capital (Series C) - 2020
Greenspring Associates Polaris Partners Two Sigma Ventures +7
$21,000,000
Venture capital (Series B) - 2018
Team Size
10+
Employees
Xconomy

Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

$112,000,000 Venture capital (Series C)
FinSMEs , AlleyWatch

Kallyope Raises $112M in Series C Financing

Xconomy

Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic

$21,000,000 Venture capital (Series B)
FinSMEs , PE HUB

Kallyope Raises $21M Expansion of Series B Financing

$66,000,000 Venture capital (Series B)
PE HUB , Xconomy

Kallyope scores $66 mln Series B

FinSMEs

Kallyope Raises $66M in Series B Financing

Science Funding